PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927704
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1927704
The Endocrine Function Diagnostics Market size was valued at US$13,120.10 Million in 2024, expanding at a CAGR of 7.97% from 2025 to 2032.
The global endocrine function diagnostics market is witnessing steady growth due to the rising prevalence of hormonal disorders, increasing incidence of diabetes and thyroid diseases, and growing demand for early and accurate diagnostic solutions. Endocrine diagnostics play a critical role in assessing hormone levels and gland function, supporting disease diagnosis, treatment planning, and long-term monitoring. Technological advancements in immunoassays, mass spectrometry, and automated analysers, along with expanding diagnostic infrastructure, are supporting market growth across developed and emerging economies.
Endocrine Function Diagnostics Market- Market Dynamics
Rising prevalence of hormonal and metabolic disorders
The increasing global burden of diabetes, thyroid disorders, adrenal dysfunction, and reproductive hormone imbalances is a major driver fueling demand for endocrine function diagnostics, as these conditions require routine hormone testing for effective disease management. Growing awareness regarding preventive healthcare and early disease detection is further accelerating test adoption. In parallel, advancements in automated diagnostic platforms, high-sensitivity assays, and portable testing solutions are improving accessibility and turnaround time. For instance, in January 2025, Eli Health launched Hormometer, a saliva-based hormone analysis device that integrates with smartphones to enable portable diagnostic testing. The platform transforms mobile devices into personal hormone analysers and initially measures cortisol and progesterone, with results delivered in approximately 20 minutes, highlighting the growing shift toward decentralised and user-friendly endocrine diagnostics.
The Global Endocrine Function Diagnostics Market is segmented on the basis of Test Type, Technology, Application, and Region.
Based on Test Type, the market is categorised into Thyroid Function Tests, Diabetes Tests, Adrenal Function Tests, Reproductive Hormone Tests, and Others. Thyroid and diabetes testing account for a significant share due to high disease prevalence worldwide. The growing incidence of lifestyle-related disorders and increased awareness of early diagnosis further drive testing demand. Additionally, these tests are routinely included in preventive health check-ups, supporting their large market share.
Based on Technology, the market is categorised into Immunoassays, Tandem Mass Spectrometry (LC-MS/MS), Enzyme-linked Assays, and Others. Immunoassays dominate the segment owing to their wide adoption, high sensitivity, and automation compatibility. Their cost-effectiveness and ability to process large sample volumes make them suitable for routine clinical use. Continuous technological advancements and the availability of standardised kits further strengthen this segment.
Based on the application, the market is categorised into Hospitals, Diagnostic Laboratories, Research Institutes, and Others. Diagnostic laboratories hold a major share due to increasing test volumes and centralised testing facilities. The expansion of diagnostic chains and growing preference for outsourced laboratory services also contribute to their market dominance.
Endocrine Function Diagnostics Market- Geographical Insights
North America leads the endocrine function diagnostics market, supported by advanced healthcare infrastructure, high awareness of hormonal disorders, and strong adoption of automated diagnostic technologies. Europe follows closely, driven by established laboratory networks and preventive screening programs. The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare expenditure, rising diabetes and thyroid disease prevalence, and expanding diagnostic capacity in countries such as China and India. Latin America and the Middle East & Africa are experiencing steady growth supported by improving healthcare access and diagnostic modernisation.
Endocrine Function Diagnostics Market- Country Insights
The United States dominates the endocrine function diagnostics market, primarily due to its high testing volumes, advantageous reimbursement policies, and the presence of established diagnostic companies that drive innovation and efficiency. This robust healthcare environment facilitates widespread access to advanced diagnostic technologies, ensuring timely detection and management of endocrine disorders. In Europe, key players from Germany, the UK, and France significantly contribute to market growth, bolstered by strong public healthcare systems and proactive early disease screening initiatives that promote preventive care. Additionally, the Asia-Pacific region, particularly China and India, is emerging as a high-growth market, fueled by large patient populations and increasing awareness of endocrine disorders. The rapid expansion of hospital and laboratory infrastructure in these countries further supports the accessibility and availability of diagnostic services. As healthcare systems in these regions evolve, they are likely to enhance the overall landscape of endocrine function diagnostics, improving patient outcomes and quality of care.
The endocrine function diagnostics market is moderately competitive, characterised by several global and regional players, including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Danaher Corporation, Thermo Fisher Scientific, bioMerieux, Sysmex Corporation, DiaSorin S.p.A., Mindray Medical International, and Ortho Clinical Diagnostics. These companies are focusing on assay innovation, automation, and expanding their test portfolios to meet healthcare demands. Significant investments are being made in high-throughput platforms, advanced immunoassays, and integrated diagnostic solutions, which enhance accuracy and workflow efficiency in laboratories. Furthermore, strategic collaborations and product launches are pivotal in reinforcing market positions. Geographic expansion remains a crucial strategy, allowing participants to tap into new markets and improve accessibility to endocrine diagnostics, for instance, in September 2024, Trinity Biotech acquired Metabolomics Diagnostics to bolster its maternal health portfolio. The acquisition provides access to deep-tech mass spectrometry and machine learning tools. This expertise supports the development of PrePsia, an early-stage preeclampsia risk test. The move marks a strategic expansion into advanced, biomarker-based diagnostic solutions. The dynamic landscape reflects a commitment to technological advancements and increased patient care quality, essential for effective monitoring and management of endocrine disorders across diverse healthcare settings.
In January 2025, Eli Health launched Hormometer, a device for saliva-based hormone analysis. The system uses smartphone technology to perform portable diagnostic testing. By integrating with mobile devices, it turns smartphones into personal analysers.
In April 2023, Eli Health raised USD 3.6 million to advance saliva-based hormone monitoring technology. The company initially focuses on improving care for menopause, fertility, and general health. Long-term plans include expansion into contraception and endocrine disease management. This growth follows the completion of critical clinical trials and regulatory requirements.